240 related articles for article (PubMed ID: 34488537)
1. Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.
Shi F; Zhang L; Liu X; Wang Y
Bioengineered; 2021 Dec; 12(1):6332-6342. PubMed ID: 34488537
[TBL] [Abstract][Full Text] [Related]
2. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis.
Ren N; Jiang T; Wang C; Xie S; Xing Y; Piao D; Zhang T; Zhu Y
Aging (Albany NY); 2020 Jun; 12(11):11025-11041. PubMed ID: 32516127
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
5. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
Han B; Liu Y; Zhang Q; Liang L
J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
[TBL] [Abstract][Full Text] [Related]
6. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
7. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
8. Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment.
Wei L; Jiang J
Bioengineered; 2021 Dec; 12(1):2499-2510. PubMed ID: 34107856
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death.
Liu J; Yao L; Zhang M; Jiang J; Yang M; Wang Y
Aging (Albany NY); 2019 Sep; 11(18):7830-7846. PubMed ID: 31553952
[TBL] [Abstract][Full Text] [Related]
10. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
12. Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis.
Ling Q; Wu S; Liao X; Liu C; Chen Y
BMC Cancer; 2022 Jul; 22(1):765. PubMed ID: 35836137
[TBL] [Abstract][Full Text] [Related]
13. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
Ma P; Han W; Meng C; Tan X; Liu P; Dong L
Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis.
Li P; Zhong X; Li J; Liu H; Ma X; He R; Zhao Y
Biochem Biophys Res Commun; 2018 Sep; 503(4):2833-2840. PubMed ID: 30119891
[TBL] [Abstract][Full Text] [Related]
15. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
16. Targeting a novel hsa_circ_0000520/miR-556-5p/NLRP3 pathway-mediated cell pyroptosis and inflammation attenuates ovalbumin (OVA)-induced allergic rhinitis (AR) in mice models.
Yu X; Wang M; Zhao H; Cao Z
Inflamm Res; 2021 Jun; 70(6):719-729. PubMed ID: 34028600
[TBL] [Abstract][Full Text] [Related]
17. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433
[TBL] [Abstract][Full Text] [Related]
19. Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axis.
Sun T; Chen J; Sun X; Wang G
Cancer Cell Int; 2021 Jul; 21(1):401. PubMed ID: 34321010
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
